Navigation Links
Ampio Pharmaceuticals, Inc. to Begin Trading on the NASDAQ Capital Market
Date:5/19/2011

GREENWOOD VILLAGE, Colo., May 19, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq Capital Market: AMPE) ("Ampio" or the "Company"), a company focused on new uses for previously approved drugs and new molecular entities ("NMEs"), today announced that its common stock will commence trading on the NASDAQ Capital Market under the ticker symbol "AMPE" commencing today, May 19, 2011.

Don Wingerter, the Company's CEO, said, "We are extremely excited to begin trading on the NASDAQ Capital Market – a milestone in our market exposure. With this listing, we will no longer trade on the OTC Bulletin Board. We believe this listing is an excellent opportunity to introduce new investors to Ampio and our vision for product candidates we are currently developing."

About Ampio

The Company is currently performing a phase II clinical trial for the treatment of diabetic macular edema and is evaluating the data from a recently completed phase III clinical trial for the treatment of premature ejaculation.  Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for metabolic disease, eye disease, kidney disease, inflammation, CNS disease, and male sexual dysfunction.  By concentrating on development of new uses for previously approved drugs, approval timelines, costs and risk of clinical failure are reduced because these drugs have strong potential to be safe and effective while their shorter development times can significantly increase near term value. A key strategy includes actively exploring partnership, licensing and other collaboration opportunities to maximize Ampio's product development programs. For more information about Ampio, please visit our website, www.ampiopharma.com.

Forward-Looking Statements

Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the m
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Ampio Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Capital Market
2. Five Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California
3. Champions Biotechnology Exercises Option to License Proprietary Compound Based on Successful Tumorgraft™ Test Results
4. Ampio Pharmaceuticals, Inc. Announces Appointment of New Chief Financial Officer to be Effective April 4, 2011
5. Kaiser Permanente Recognized as a J.D. Power 2011 Customer Service Champion
6. CHAMPION Study Published in The Lancet
7. Champions CFO Resigns
8. Champions Biotechnology Awarded $1.46 million in Grants
9. Two-Time Super Bowl Champion Coach & Sports Broadcaster Jimmy Johnson Laughs About His Notoriety in New ExtenZe Spots from Inter/Media Advertising
10. Dr. Brian Boxer Wachler to be Honored With Olympic Gold Medal Bobsled Champion Steve Holcomb Alongside Apple CEO Steve Jobs, James Cameron, Dan Rather, Quincy Jones and Others at 2010 Vision Awards in Beverly Hills
11. Champions Biotechnology Announces Agreement With Cephalon for the Evaluation of a Novel Oncology Compound Using Predictive Biomerk Tumorgraft™ Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014  Medical Diagnostic Laboratories, L.L.C., (MDL), ... high complexity, state-of-the-art, automated DNA-based molecular analyses, ... Cystic Fibrosis Testing which utilizes cutting edge ... Cystic fibrosis (CF), or mucoviscidosis, ... affects the respiratory, gastrointestinal and reproductive systems. ...
(Date:10/22/2014)... Oct. 22, 2014  Rescheduling of hydrocodone combination ... the pain market, according to a new primary ... firm providing market research and consultation exclusively in ... - http://photos.prnewswire.com/prnh/20141021/153440 In ... hydrocodone combination products from Schedule III to Schedule ...
(Date:10/22/2014)... -- Investor-Edge has initiated coverage on the ... ), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX ), ... Pharmaceuticals Inc. (NASDAQ: IDRA ), and Merrimack ... companies can be accessed at: http://investor-edge.com/register . ... ended at 4,419.48, up 2.40%, the Dow Jones Industrial ...
Breaking Medicine Technology:Medical Diagnostic Laboratories, L.L.C. Institute for Biomarker Research Announces New Prenatal Cystic Fibrosis Tests 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5
(Date:10/25/2014)... (PRWEB) October 25, 2014 QueenBeeTickets.com has ... a great selection at affordable prices. Bob Seger & ... Huntington Center and Nationwide Arena are going on sale ... Click Here to browse the selection of ... at QueenBeeTickets.com. , The famous singer is touring North ...
(Date:10/25/2014)... FRIDAY, Oct. 24, 2014 (HealthDay News) -- Interrupting blood supply ... help reduce the risks associated with the surgery, according to ... to stop the blood supply to the heart to be ... blood, the heart will reduce its ability to produce energy ... blood flow to another large muscle, such as an arm ...
(Date:10/25/2014)... Oct. 23, 2014 (HealthDay News) -- Current osteoporosis ... younger postmenopausal women at risk for osteoporosis-related fractures, ... to prevent fractures, we need tools that help ... injuries so that we can target these at-risk ... Crandall, professor of medicine in the division of ...
(Date:10/22/2014)... On October 22, CBS will air an episode ... fictional and real. The Charles E Holman Morgellons ... advocacy and philanthropy in the battle against Morgellons Disease, ... impart truth and clarity about this misunderstood and routinely ... about Morgellons Disease (MD) and most people ...
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- The ... passengers arriving from Ebola-affected nations of West Africa ... screen them for infection with the virus. ... Jeh Johnson noted that 94 percent of air ... land at one of these five airports -- ...
Breaking Medicine News(10 mins):Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3
... the secure,remote service and support company today announced ... MCK ), has selected,the Axeda(R) ServiceLink solution ... which ensure safety and accuracy throughout the,medication use ... Axeda(R) Software Management,application will be used to remotely ...
... mission-critical outsourcing to Brooke Army Medical Center, ... SINT ), an information technology and network ... a new competitive task order under,the US Army,s ... Personnel Service and Support to provide,services to Brooke ...
... CHARLES TOWN, W.Va., Oct. 16 ReBuilder,Medical Technologies, ... agreed upon a Joint Venture with UFFE Medical, ... ReBuilder Medical,s unique home treatment for,the skin disease ... sometimes hundreds of pimple-like lesions that can take ...
... has been named one of 10 new centers in ... make critical treatment decisions about therapeutic products and interventions. ... for Healthcare Research and Quality,s Center for Education and ... and test systems to optimize drug choice, monitoring and ...
... Today, the International Association for the Study of Pain (IASP) ... to draw attention to the significant impact of chronic pain ... Lack of awareness of pain issues affecting women and ... of millions of women. , Chronic pain affects a ...
... Discovery could lead to new therapies , TUESDAY, Oct. 16 ... cancer has been identified. The finding about the Dmp1 ... at the cellular level to cause lung cancer. , The ... of human non-small-cell lung cancers and found that the ...
Cached Medicine News:Health News:Axeda Selected for Remote Monitoring and Service of Automation Technologies 2Health News:SI International Awarded $4 Million Army HRsolutions Task Order 2Health News:SI International Awarded $4 Million Army HRsolutions Task Order 3Health News:ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase. 2Health News:ReBuilder Medical Technologies, Inc. Announces UK Demand for Safe Molluscum Contagiosum Treatment Leads to Distribution Agreement with UFFE Medical, LTD. Expected 10% Sales Increase. 3Health News:New UIC center to study drug choices, safety 2Health News:IASP declares the Global Year Against Pain in Women 2Health News:IASP declares the Global Year Against Pain in Women 3Health News:Researchers ID New Gene Linked to Lung Cancer 2
... Ureteral Stents have all the advantages ... addition, a unique 360 degree kidney ... placement in the renal pelvis or ... remarkably comfortable stent, ideal for use ...
All the advantages of Dr. Roy P. Finney's classic stent design with an open tip....
This EIA microplate opens new perspectives in the direct detection of Chlamydia. The choice of microplate immunoenzymatic technology and the use of a monoclonal antibody result in a combination of c...
Inquire...
Medicine Products: